 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 February 2001 | Volume 134 Issue 3 | Pages 224-238
Purpose: To describe the characteristics of thrombus formation on atherosclerotic plaques, the clinical expression of atherothrombosis in vascular disease, and some of the most recent therapeutic approaches in cardiovascular disease.
Data Sources: MEDLINE search for English-language articles on thrombosis and atherosclerosis published up to January 2000. Abstracts of recent international meetings on new aspects of thrombus formation and new therapeutic options were reviewed, and references from identified articles were selected and reviewed.
Study Selection: Experimental, basic, clinical, and epidemiologic studies related to the pathophysiology of thrombosis on atherosclerotic lesions. Therapeutic approaches were obtained from experimental studies and large clinical investigations.
Data Extraction: Arterial vessel wall substrate, rheologic conditions, and blood thrombogenicity influence the process of thrombus formation in arteries. Thrombus formation on disrupted atherosclerotic plaques or arterial erosions frequently causes acute coronary syndromes. Severe atherosclerosis of the aorta has been identified as an important morphologic indicator of an increased risk for thromboembolism. Current antithrombotic therapies available as long-term treatment for patients with cardiovascular disease are often not effective enough to prevent acute thrombotic events and deterioration of atherosclerosis.
Data Synthesis: Improved understanding of the pathophysiology of thrombus formation on atherosclerotic plaques has led to the development of new therapeutic approaches. Glycoprotein IIb/IIIa, tissue factor, factor Xa, and thrombin inhibitors as well as combined antithrombotic therapy, such as aspirin plus a thienopyridine plus warfarin, are being evaluated as new possible options for the treatment of arterial thrombosis.
Conclusions: Long-term treatment with potent antithrombotic drugs, such as tissue factor or factor Xa inhibitors, that effectively block thrombosis without causing bleeding complications could help reduce death from cardiovascular disease.
Author and Article Information
From the Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York.
Grant Support: By the National Institutes of Health SCOR on Thrombosis (P50 HL54469).
Requests for Single Reprints: James H. Chesebro, MD, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1030, New York, NY 10029; e-mail, james.chesebro{at}mssm.edu.
Current Author Addresses: Dr. Rauch: Benjamin Franklin Clinic, Department of Cardiology, Free University of Berlin, Berlin, Germany.
Drs. Osende, Fuster, Badimon, Fayad, and Chesebro: The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1030, New York, NY 10029. REVIEW
Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences
This article has been cited by other articles:
|
|
 |
|
  R. Lu, A. Alioua, Y. Kumar, P. Kundu, M. Eghbali, N. V. Weisstaub, J. A. Gingrich, E. Stefani, and L. Toro c-Src tyrosine kinase, a critical component for 5-HT2A receptor-mediated contraction in rat aorta J. Physiol., August 15, 2008; 586(16): 3855 - 3869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, et al. Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad Eur. Heart J., July 2, 2008; 29(14): 1729 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Goldin-Lang, K. Pels, Q.-V. Tran, B. Szotowski, F. Wittchen, S. Antoniak, T. Willich, H. Witt, M. Hummel, D. Lenze, et al. Effect of ionizing radiation on cellular procoagulability and co-ordinated gene alterations Haematologica, August 1, 2007; 92(8): 1091 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Piorkowski, S. Fischer, C. Stellbaum, M. Jaster, P. Martus, A. J. Morguet, H.-P. Schultheiss, and U. Rauch Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone: Is Sufficient Cholesterol-Lowering Enough to Inhibit Platelets? J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1035 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Szotowski, S. Antoniak, P. Goldin-Lang, Q.-V. Tran, K. Pels, P. Rosenthal, V. Y. Bogdanov, H.-H. Borchert, H.-P. Schultheiss, and U. Rauch Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells Cardiovasc Res, March 1, 2007; 73(4): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Saloner, G. Acevedo-Bolton, M. Wintermark, and J. H. Rapp MRI of Geometric and Compositional Features of Vulnerable Carotid Plaque Stroke, February 1, 2007; 38(2): 637 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Stoll and M. Bendszus Inflammation and Atherosclerosis: Novel Insights Into Plaque Formation and Destabilization Stroke, July 1, 2006; 37(7): 1923 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Sinnaeve, J. Simes, S. Yusuf, J. Garg, S. Mehta, J. Eikelboom, J. A. Bittl, P. Serruys, E. J. Topol, and C. B. Granger Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention Eur. Heart J., November 2, 2005; 26(22): 2396 - 2403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts J. Am. Coll. Cardiol., September 20, 2005; 46(6): 937 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Steptoe, J. Wardle, and M. Marmot Positive affect and health-related neuroendocrine, cardiovascular, and inflammatory processes PNAS, May 3, 2005; 102(18): 6508 - 6512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Szotowski, P. Goldin-Lang, S. Antoniak, V. Y. Bogdanov, D. Pathirana, M. Pauschinger, A. Dorner, U. Kuehl, S. Coupland, Y. Nemerson, et al. Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1081 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jerjes-Sanchez Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur. Heart J., January 1, 2005; 26(1): 3 - 4. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ovbiagele, C. S. Kidwell, and J. L. Saver Expanding Indications for Statins in Cerebral Ischemia: A Quantitative Study Arch Neurol, January 1, 2005; 62(1): 67 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Goto Propagation of Arterial Thrombi: Local and Remote Contributory Factors Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2207 - 2208. [Full Text] [PDF]
|
|
|
|
|
|
J. F Viles-Gonzalez, V. Fuster, and J. J Badimon Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences Eur. Heart J., July 2, 2004; 25(14): 1197 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aljada, H. Ghanim, P. Mohanty, T. Syed, A. Bandyopadhyay, and P. Dandona Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations Am. J. Clinical Nutrition, July 1, 2004; 80(1): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Priebe Triggers of perioperative myocardial ischaemia and infarction Br. J. Anaesth., July 1, 2004; 93(1): 9 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Faxon, V. Fuster, P. Libby, J. A. Beckman, W. R. Hiatt, R. W. Thompson, J. N. Topper, B. H. Annex, J. H. Rundback, R. P. Fabunmi, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: Pathophysiology Circulation, June 1, 2004; 109(21): 2617 - 2625. [Full Text] [PDF]
|
|
|
|
 |
|
 M Jaster, V Fuster, P Rosenthal, M Pauschinger, Q-V Tran, D Janssen, W Hinkelbein, P Schwimmbeck, H-P Schultheiss, and U Rauch Catheter based intracoronary brachytherapy leads to increased platelet activation Heart, February 1, 2004; 90(2): 160 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sartipy and D. J. Loskutoff Expression Profiling Identifies Genes That Continue to Respond to Insulin in Adipocytes Made Insulin-resistant by Treatment with Tumor Necrosis Factor-{alpha} J. Biol. Chem., December 26, 2003; 278(52): 52298 - 52306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jneid, D. L. Bhatt, R. Corti, J. J. Badimon, V. Fuster, and G. S. Francis Aspirin and Clopidogrel in Acute Coronary Syndromes: Therapeutic Insights From the CURE Study Arch Intern Med, May 26, 2003; 163(10): 1145 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. van Gestel, J. W.M. Heemskerk, D. W. Slaaf, V. V.T. Heijnen, R. S. Reneman, and M. G.A. oude Egbrink In Vivo Blockade of Platelet ADP Receptor P2Y12 Reduces Embolus and Thrombus Formation but Not Thrombus Stability Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 518 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Corti, V. Fuster, and J. J. Badimon Pathogenetic concepts of acute coronary syndromes J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 7S - 14S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dandona, A. Aljada, and A. Bandyopadhyay The Potential Therapeutic Role of Insulin in Acute Myocardial Infarction in Patients Admitted to Intensive Care and in Those With Unspecified Hyperglycemia Diabetes Care, February 1, 2003; 26(2): 516 - 519. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Steptoe, S. Kunz-Ebrecht, N. Owen, P. J. Feldman, A. Rumley, G. D. O. Lowe, and M. Marmot Influence of Socioeconomic Status and Job Control on Plasma Fibrinogen Responses to Acute Mental Stress Psychosom Med, January 1, 2003; 65(1): 137 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Rubins, S. J. Robins, D. Collins, D. B. Nelson, M. B. Elam, E. J. Schaefer, F. H. Faas, J. W. Anderson, and for the VA-HIT Study Group Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Arch Intern Med, December 9, 2002; 162(22): 2597 - 2604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Gorelick Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy: An Invited Review Stroke, March 1, 2002; 33(3): 862 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Podor, D. Singh, P. Chindemi, D. M. Foulon, R. McKelvie, J. I. Weitz, R. Austin, G. Boudreau, and R. Davies Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface J. Biol. Chem., February 22, 2002; 277(9): 7529 - 7539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Kunicki The Influence of Platelet Collagen Receptor Polymorphisms in Hemostasis and Thrombotic Disease Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 14 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. POBER, C. S. NEUHAUSER, and J. M. POBER Obstacles facing translational research in academic medical centers FASEB J, November 1, 2001; 15(13): 2303 - 2313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Kunicki and Z. M. Ruggeri Platelet Collagen Receptors and Risk Prediction in Stroke and Coronary Artery Disease Circulation, September 25, 2001; 104(13): 1451 - 1453. [Full Text] [PDF]
|
|
Article
